Hayashi M, Madokoro H, Yamada K, Nishida H, Morimoto C, Sakamoto M, Yanagawa H, Yamada T. Novel antibody-drug conjugate with anti-CD26 humanized monoclonal antibody and transcription factor IIH (TFIIH) inhibitor, triptolide, inhibits tumor rrowth via impairing mRNA synthesis. Cancers. 2019. 11. 8. 1138-1138
Nishida H, Hayashi M, Morimoto C, Sakamoto M, Yamada T. CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma. Blood Cancer Journal. 2018. 8. 99
Hayashi M, Madokoro H, Yamada K, Nishida H, Morimoto C, Sakamoto M, Yamada T. A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition. Cancer Cell International. 2016. 16. 35
Nishida H, Suzuki H, Madokoro H, Hayashi M, Morimoto C, Sakamoto M, Yamada T. Blockade of CD26 Signaling Inhibits Human Osteoclast Development. J Bone Mineral Research. 2014. 29. 11. 2439-2455
Yamada K, Hayashi M, Madokoro H, Nishida H, Du W, Ohnuma K, Sakamoto M, Morimoto C, Yamada T. Nuclear Localization of CD26 Induced by a Humanized Monoclonal Antibody Inhibits Tumor Cell Growth by Modulating of POLR2A Transcription. PLoS One. 2013. 8. 4. e62304